Trevena Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TRVN Nasdaq 8731 https://www.trevena.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Trevena Inc

Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical - May 31st, 2023 11:00 am
Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones - May 30th, 2023 11:00 am
Q1 2023 Trevena Inc Earnings Call - May 16th, 2023 1:01 am
Trevena Reports First Quarter 2023 Results and Provides Business Update - May 15th, 2023 11:00 am
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates - May 11th, 2023 9:25 pm
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023 - May 9th, 2023 11:00 am
Trevena Announces Approval of OLINVYK in China - May 8th, 2023 11:00 am
Trevena to Participate in Three Upcoming Conferences - May 3rd, 2023 11:00 am
Trevena, Inc. (NASDAQ:TRVN) Q4 2022 Earnings Call Transcript - Apr 9th, 2023 11:34 pm
Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study - Mar 30th, 2023 11:02 am
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update - Mar 30th, 2023 11:00 am
Trevena to Release Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023 - Mar 27th, 2023 11:00 am
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate - Mar 9th, 2023 3:21 pm
Trevena Initiates Targeted Proof-of-Concept Study to Evaluate TRV045 as a Potential Treatment for Epilepsy and Other CNS Disorders - Mar 7th, 2023 12:00 pm
Trevena Announces Publication of OLINVYK Respiratory Physiology Study In ANESTHESIOLOGY - Feb 14th, 2023 1:00 pm
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement - Jan 9th, 2023 12:00 pm
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings - Dec 8th, 2022 12:00 pm
Trevena Regains Compliance with Nasdaq Listing Requirements - Nov 29th, 2022 12:00 pm
Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Nov 16th, 2022 1:00 pm
Trevena Announces Reverse Stock Split - Nov 9th, 2022 9:01 pm